Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss

(204122)
(Formerly Chromosomal Microarray Analysis for the Evaluation of Pregnancy Loss)

Medical Benefit
Effective Date: 04/01/16
Next Review Date: 11/18
Preauthorization
No
Review Dates: 09/14, 05/15, 11/15, 01/16, 11/16, 11/17

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • With pregnancy loss with indications for genetic analysis of the embryo or fetus</td>
<td>Interventions of interest are: • Chromosomal microarray testing of fetal tissue</td>
<td>Comparators of interest are: • Karyotype of fetal tissue</td>
<td>Relevant outcomes include: • Test accuracy • Test validity • Other test performance measures • Changes in reproductive decision making • Morbid events • Quality of life</td>
</tr>
</tbody>
</table>

Description
Chromosomal microarray testing (CMA) of fetal tissue or placental tissue derived from the fetal genotype has been proposed as a technique to evaluate the cause of isolated and recurrent early pregnancy loss (miscarriages) and later pregnancy loss (intrauterine fetal demise [IUFD]). The evaluation of both recurrent and isolated miscarriages and IUFD may involve genetic testing of the products of conception (POC). Such testing has typically been carried out through cell culture and karyotyping of cells in metaphase. However, the analysis of fetal or placental tissue has been inhibited by the following limitations: the need for fresh tissue, the potential for cell culture failure, and the potential for maternal cell contamination.

Summary of Evidence
For individuals who have pregnancy loss with indications for genetic analysis of the embryo or fetus who receive CMA testing of fetal tissue, the evidence includes prospective and retrospective cohort studies that report on the yield of CMA testing. Relevant outcomes are test accuracy and validity, other test performance measures, changes in reproductive decision making, morbid events, and quality of life. The available evidence has suggested that CMA testing has a high rate of concordance with standard karyotyping. For both early and late pregnancy loss, CMA is more likely to yield a result than karyotyping. Other studies have reported that CMA testing
detects a substantial number of abnormalities in patients with normal karyotypes, although the precise yield is uncertain and likely varies based on gestational age. Rates of variants of uncertain significance in CMA testing of miscarriage samples are not well characterized. Potential benefits from identifying a genetic abnormality in a miscarriage or IUFD include reducing emotional distress for families, altering additional testing undertaken to assess for other causes of pregnancy loss, and changing reproductive decision making for future pregnancies. The potential for clinical utility with CMA testing of fetal tissue in pregnancy loss is parallel to that for obtaining a karyotype of fetal tissue in pregnancy loss, which is recommended by a number of organizations. None of the studies identified directly demonstrated whether (or how) patient management would change based on CMA testing of POC from early or late pregnancy losses, nor did they demonstrate how patient outcomes would improve; however, the available evidence suggests that, for situations in which a genetic evaluation is indicated, CMA testing would be expected to perform as well as (or better) than standard karyotyping. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy

Chromosomal microarray testing of fetal tissue may be considered medically necessary for the evaluation of pregnancy loss in patients with indications for genetic analysis of the embryo or fetus (see Policy Guidelines).

Policy Guidelines

In cases of miscarriage or IUFD where genetic analysis of the embryo or fetus, or stillborn infant is indicated, certain guidelines are followed. These guidelines, which specifically address the use of karyotyping and/or microarray testing in miscarriage or IUFD, were developed by several reproductive health associations, including the American Society for Reproductive Medicine (ASRM, 2013; ASRM, 2012), the National Society of Genetic Counselors (Laurino et al, 2005), and the American College of Obstetrics and Gynecology (ACOG, 2009). Per such guidelines, genetic testing may be indicated (if desired by parents):

- In cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of two or more failed pregnancies); OR
- In all cases of pregnancy loss after 20 weeks of gestation.

The decision to obtain genetic testing should be made jointly by the mother or parents and the treating clinician. This protocol does not address the use of chromosomal microarray testing for preimplantation genetic diagnosis or preimplantation genetic screening, or the evaluation of suspected chromosomal abnormalities in the postnatal period.

Genetics Nomenclature Update

Human Genome Variation Society (HGVS) nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. Such nomenclature is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). HGVS nomenclature is recommended by HGVS, the Human Variome Project, and the HUman Genome Organization (HUGO).

The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) standards and guidelines for interpretation of sequence variants represent expert opinion from ACMG, AMP, and the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.
Table PG1. Nomenclature to Report

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
<td>Disease-associated change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td>Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
<td></td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associated variant</td>
<td>Change in the DNA sequence</td>
</tr>
</tbody>
</table>

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual’s family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Definitions

Fetal tissue may consist of fetal tissue, a formed fetus, or placental tissue derived from the fetal genotype, depending on the stage of pregnancy at the time of the fetal loss.

Early pregnancy loss or miscarriage is considered to be a pregnancy loss that occurred at or before 20 weeks gestational age.

Intrauterine fetal demise is defined as delivery of a non-live-born fetus after 20 weeks gestational age.

Background

Pregnancy Loss: Etiology and Evaluation

Early Pregnancy Loss

Pregnancy loss is common, occurring in at least 15% to 25% of recognized pregnancies. Most pregnancy loss occurs early in the pregnancy, most often by the end of the first trimester or early second trimester. Pregnancy loss that occurs before the 20th week of gestation is referred to as a spontaneous abortion, early pregnancy loss, or miscarriage. While a wide range of factors can lead to early pregnancy loss, genetic causes are thought to be the predominant cause: when products of conception (POC) are examined, it is estimated that 60% of early pregnancy losses are associated with chromosomal abnormalities, particularly trisomies and monosomy X.1,2 The increasing risk of trisomies with maternal age contributes to the increased risk of early pregnancy loss with increasing maternal age.

Recurrent pregnancy loss, defined by the American Society for Reproductive Medicine (ASRM) as two or more failed pregnancies, is less common, occurring in approximately 5% of women.3 Recurrent pregnancy loss may be
related to cytogenetic abnormalities, particularly balanced translocations, uterine abnormalities, thrombophilias, including antiphospholipid syndrome, and metabolic or endocrinologic disorders such as uncontrolled diabetes and thyroid disease. Estimates for the frequency of various underlying causes of recurrent pregnancy loss vary widely, with ranges from 2% to 6% for cytogenetic abnormalities, 8% to 42% for antiphospholipid antibody syndrome, and 1.8% to 37.6% for uterine abnormalities. It is likely that the risk of cytogenetic abnormalities is lower in recurrent early pregnancy loss than in isolated spontaneous early pregnancy loss.

Clinicians and patients may evaluate for the cause of a single or recurrent early pregnancy loss for several reasons. The knowledge that an early pregnancy loss is secondary to a sporadic genetic abnormality may provide parents with reassurance that there was nothing that they did or did not do that contributed to the loss, although the magnitude of this benefit is difficult to quantify. For couples with recurrent pregnancy loss and evidence of a structural genetic abnormality in one of the parents, preimplantation genetic diagnosis with transfer of unaffected embryos or the use of donor gametes might be considered for therapy. These therapies might be considered for couples with recurrent pregnancy loss without evidence of a structural genetic abnormality in one of the parents; 2012 guidelines on the management of recurrent pregnancy loss from ASRM indicate that “treatment options should be based on whether repeated miscarriages are euploid, aneuploid, or due to an unbalanced structural rearrangement and not exclusively on the parental carrier status.” Finally, among patients who are found to have a potential nongenetic underlying cause of recurrent pregnancy loss, such as antiphospholipid syndrome, cytogenetic analysis of pregnancy losses may provide evidence that the miscarriages were not due to treatment failure.

Genetic testing of POC, if possible, is recommended by several reproductive health organizations. A 2012 committee opinion from ASRM recommended that the assessment of recurrent pregnancy loss include peripheral karyotyping of the parents and states that karyotypic analysis of POC may be useful in the setting of ongoing therapy for recurrent pregnancy loss. The National Society of Genetic Counselors convened a multidisciplinary working group that recommended, for the genetic evaluation of couples with recurrent pregnancy loss, chromosomal analysis of fetal tissue from POC be pursued (when possible).

Late Pregnancy Loss

Fetal loss that occurs later in pregnancy, after 20 weeks of gestation, may be referred to as IUFD, stillbirth, or intrauterine fetal death. In 2004, IUFD occurred in 6.2 of 1000 births in the United States, representing about 60% of perinatal mortality. IUFD may be related to a range of disorders, including genetic disorders in the fetus, maternal infection, coexisting maternal medical disorders (e.g., diabetes, anti-phospholipid antibody syndrome, heritable thrombophilias), and obstetric complications. Chromosomal or genetic abnormalities can be found in 8% to 13% of IUFD, most commonly aneuploidies. In a large 2012 series of IUFD (N=1025), cytogenic abnormalities were detected in 11.9%.

The American College of Obstetrics and Gynecology has recommended that evaluation after an IUFD includes examination of the stillborn fetus, along with examination of the placenta and umbilical cord and genetic testing for all IUFD (after parental permission is obtained). Other evaluation should be based on maternal history and may include evaluation for thyroid disorders, systemic lupus erythematosus, and infections.

Reasons for evaluation for a cause of IUFD are similar to those for earlier pregnancy loss. Although both early and later pregnancy losses may cause grief for the mother and her family, IUFD can be particularly devastating. Information about the cause of the pregnancy loss may be important in counseling women about their recurrence risk. In low-risk women with an unexplained IUFD, the risk of recurrence is 7.8 to 10.5 per 1000 live births, but this increases to 21.8 per 1000 live births in women with a history of fetal growth restriction. Identification of a heritable genetic mutation in a fetus may prompt testing in the parents; if a heritable mutation is identified, parents may pursue preimplantation genetic diagnosis in future pregnancies.
Genetic Abnormalities in Miscarriage and IUFD

Genetic disorders are generally categorized into three groups: single gene, chromosomal, and multifactorial. Single-gene disorders (also known as monogenic disorders) result from errors in a specific gene, whereas those that are chromosomal include larger aberrations that are numerical or structural. Evidence about specific abnormalities in miscarriages and IUFD is somewhat limited; however, it is estimated that 60% of early pregnancy losses are associated with chromosomal abnormalities, particularly trisomies and monosomy X. For later pregnancy losses, aneuploidies are most common in the 8% to 13% of tested IUFD that have an identified chromosomal or genetic abnormality. Karyotypic abnormalities are identified in 6% to 12% of IUFD. Rates of single-gene disorders in IUFD are less well-quantified. However, of stillborn fetuses who undergo autopsy, 25% to 35% are identified to have single or multiple malformations or deformations; of these, 25% have an abnormal karyotype, but other single-gene disorders are suspected to occur in a high proportion of stillborn fetuses with malformations.

Traditionally, genetic evaluation of the POC after a miscarriage is conducted by karyotyping of metaphase cells after cells are cultured in tissue. Karyotyping can identify whole-chromosome aneuploidies and large structural rearrangements; however, only visible rearrangements are likely to be identified using this method (down to a resolution of 5-10 Mb), so smaller genetic variants may not be detected. In addition, karyotype requires culturing the target cells, which may fail or be infeasible, particularly for formalin-preserved samples. In addition, there is the potential for maternal cell contamination, which may occur if the POC tissue is not separated from the maternal decidua before culturing, or if there is poor growth of noneuploid cells from the POC tissue, thereby allowing maternal cell overgrowth. The potential for maternal cell contamination makes it impossible to know if a normal female (46 XX) karyotype testing result is due to a normal fetal karyotype or a maternal karyotype. A 2009 study that included 103 first trimester miscarriages, culture failure occurred in 25% of cases.

Chromosomal Microarray Testing

There is interest in using alternative genetic testing methods, particularly array comparative genomic hybridization (aCGH), to detect chromosomal or other genetic abnormalities in the evaluation of miscarriages and IUFD.

Types of Chromosomal Microarray Technologies

Several types of microarray technology are in current clinical use, primarily aCGH and single-nucleotide polymorphism (SNP) microarrays. Comparative genomic hybridization (CGH) CMA testing detects copy number variants (CNVs) by comparing a reference genomic sequence with the patient (“unknown”) sequence in terms of binding to a microarray of cloned (from bacterial artificial chromosomes) or synthesized DNA fragments with known sequences. The reference DNA and the unknown sample are labelled with different fluorescent tags, and both samples are cohybridized to the fragments of DNA on the microarray. Computer analysis is used to detect the array patterns and intensities of the hybridized samples. If the unknown sample contains a deletion or duplication of genetic material in a region contained on the reference microarray, the sequence imbalance is detected as a difference in fluorescence intensity.

In SNP-based CMA testing, a microarray of SNPs, which may include hundreds of thousands of SNPs, is used for hybridization. In contrast with aCGH, a reference genomic sequence is not used. Instead, only the “unknown” sample is hybridized to the array platform, and the presence or absence of specific known DNA sequence variants is evaluated by signal intensity to provide information about copy numbers. In some cases, laboratories confirm CNVs detected on CMA with an alternative technique, such as fluorescence in situ hybridization or flow cytometry.

Microarrays also vary in breadth of coverage of the genome that they include. Targeted CMA provides coverage of the genome with a concentration of sequences in areas with known, clinically significant CNVs. In contrast,
whole-genome CMA allows the characterization of large numbers of genes, but with the downside that analysis may identify large numbers of CNVs of undetermined significance.

CMA Compared With Karyotyping

CMA has several advantages over karyotyping, including improved resolution (detection of smaller chromosomal variants that are undetectable using standard karyotyping), and therefore can result in potentially higher rates of detection of pathogenic chromosomal abnormalities. Array CGH can detect CNVs for larger deletions and duplications, including trisomies. However, CMA based on aCGH cannot detect balanced translocations or diploid, triploid, and tetraploid states, or sequence inversions because they are not associated with fluorescence intensity change. SNP-based CMA, in addition to detecting deletions and duplications, can detect runs of homozygosity, which suggests consanguinity, triploidy, and uniparental disomy.

Another advantage of CMA is that it does not require successful cell culture, so it is more likely to yield a result in cases where karyotyping is technically unsuccessful due to failed culture. In the case of testing of specimens from early miscarriage, CMA may also be used to rule out maternal cell contamination, if a fetal sample is compared with a maternal sample.

One distinct disadvantage of CMA is its higher rates of detection of variants of uncertain significance. In 2011, the American College of Medical Genetics (ACMG) published guidelines on the interpretation and reporting of CNVs in the postnatal setting. ACMG recommended that laboratories performing array-based assessment of CNVs track their experience with CNVs and document pathogenic CNVs, CNVs of uncertain significance, and CNVs determined to represent benign variations based on comparisons with internal and external databases.9

Commercially Available Tests

Natera Inc. (San Carlos, CA) offers the Anora™ miscarriage test, which uses a SNP-based array system for testing of POC. The test includes the company’s proprietary “Parental Support Technology,” which uses a DNA sample from one or both parents as a reference to the POC sample. This comparison can identify maternal cell contamination, uniparental disomy, and the parent of origin of a fetal chromosome abnormality. According to a description of the “Parental Support” algorithm,10 the algorithm uses the

“SNP array data to calculate the relative amounts of each of the 2 alleles at each SNP. At heterozygous loci, disomic chromosomes are expected to have SNP ratios of approximately 50%, trisomic chromosomes are expected to have SNP ratios of approximately 33% and 66%, and monosomic chromosomes are expected to have only homozygous loci. For each chromosome, the algorithm compares the observed SNP data to each of the expected alleles for the possible ploidy states and determines which is most likely.”

According to the manufacturer’s website, the test reports the following abnormalities, including the parent of origin of any anomaly when a parental sample has been submitted11:

- Any whole chromosome aneuploidy.
- Triploidy.
- Tetraploidy where one parent contributed one set of chromosomes and the other parent contributed the other three. Tetraploidy when parental contribution is equal cannot be detected.
- Uniparental disomy.
- Interstitial deletions and duplications greater than five megabase (Mb) pairs.
- Any terminal deletion or duplication, because it could be an indication for a balanced translocation.
• Deletions of one Mb or greater and duplications of two Mb or greater are reviewed individually by a genetic counselor or geneticist and reported if the potential cause of a miscarriage or recurrence risk implications are identified.

• Any of the following deletions and duplications, when identified:
  o 1p36 deletion
  o 1q21.1 deletion (epilepsy)
  o 2q37 deletion
  o 3q29 terminal deletion
  o 4p16.3 deletion (Wolf-Hirschhorn syndrome)
  o 5p15.2 deletion (cri du chat)
  o 7q11.23 deletion (Williams syndrome)
  o 8q23.2-8q24.1 deletion (Langer-Giedion syndrome)
  o 9q34 deletion
  o 11p13-14 deletion (WAGR syndrome)
  o 11q24.1 deletion (Jacobsen syndrome)
  o 10p13-p14 deletion (DiGeorge syndrome)
  o 15q11-q13 deletion (Prader-Willi and Angelman syndrome)
  o 16p11.2 deletion (epilepsy)
  o 17p11.2 deletion (Smith-Magenis syndrome)
  o 17p13.3 deletion (Miller-Dieker syndrome)
  o 17q21.31 deletion
  o 22q13 deletion (Phelan-McDermid syndrome)
  o 22q11.2 deletion (DiGeorge syndrome/velocardiofacial syndrome)
  o 22q11.2 duplication
  o Xq28 deletion (MECP2 deletion)
  o Xq28 duplication (MECP2 duplication)

CombiMatrix (Irvine, CA) offers the CombiSNP™ Array for Pregnancy Loss, which is used to test fresh tissue samples, formalin-fixed, paraffin-embedded tissue samples, or unstained slides. According to the manufacturer’s website, the CombiSNP Array is a high-resolution SNP microarray that can detect triploidy, numeric chromosome abnormalities, unbalanced structural rearrangements, microdeletion/duplication syndromes, long stretches of homozygosity, which can indicate shared ancestry or uniparental disomy, and maternal cell contamination. The company also offers maternal cell contamination studies.12

GeneDx offers the Whole Genome Chromosomal Microarray for Products of Conception test, which is a SNP and aCGH that has whole genome aCGH coverage with oligonucleotide probes for the detection of CNVs and SNP probes to detect runs of homozygosity, which may indicate uniparental disomy.

Multiple laboratories offer CMA testing for prenatal samples that is not specifically designed for testing of POC.
Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA). The Anora™ miscarriage test, the CombiSNP™ Array for Pregnancy Loss, the CombiBAC™ Array, and the GeneDx Whole Genome Chromosomal Microarray for Products of Conception, along with other CMA testing platforms currently available are LDTs available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Related Protocols

Carrier Screening for Genetic Diseases
Genetic Testing for Developmental Delay and Autism Spectrum Disorder
Preimplantation Genetic Testing

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


